Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$16.03 +1.97%

+$0.38 today

Market cap
$3.00B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.44M

Average 1.71M

Returns on capital

Dyne Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-45.9%

avg -48.4%

ROIC

-41.0%

avg -52.6%

ROA

-37.6%

avg -43.8%

Analysis

ROA is currently the strongest return metric at -37.6% versus its period average of -43.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

John G. Cox

Chief Executive Officer, President & DirectorUSD 1.14M63——

Johanna Friedl-Naderer

Chief Commercial OfficerUSD 842.75K58152.90K0.09%

Douglas Kerr

Head of Research & Development and Chief Medical OfficerUSD 748.07K5912.00K<0.01%

Oxana Beskrovnaya

Chief Innovation OfficerUSD 740.48K65195.84K0.12%

Erick J. Lucera

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and TreasurerUSD 726.89K58——

Alessandro Martuscelli

Chief Legal Officer————

James Bilotta

Chief Digital & Information Officer————

Debra Feldman

Chief Regulatory Affairs Officer—55——

Lucia Celona

Chief Human Resource Officer—60——

Rajesh Manchanda

Chief Technical Officer—59——

Axel Wiest

Senior VP and Head of Portfolio Strategy & Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 20, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

8

$314,840.00

Sells

122

$168.62M

Net Transaction Value

−$168.30M

Net selling

Most Active

Rhodes Jason P

79 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 2, 26

Posner Brian S

Direct

Buy$40K
Sep 8, 26

Kerr Douglas

Direct

Sell$24.4K
Sep 8, 26

Cox John

Direct

Sell$106.8K
Sep 8, 26

Friedl-Naderer Johanna

Direct

Sell$3.5K
Sep 4, 26

Kerr Douglas

Direct

Sell$91.2K
Sep 4, 26

Friedl-Naderer Johanna

Direct

Sell$21.9K
Aug 14, 26

Rhodes Jason P

Indirect

Sell$8.1M
Aug 14, 26

Rhodes Jason P

Indirect

Sell$34M
Aug 14, 26

Rhodes Jason P

Indirect

Sell$12M
Aug 13, 26

Kerr Douglas

Direct

Sell$40.9K

1–10 of 130

Summary

Insiders reported 8 buys worth $314,840.00 and 122 sells worth $168.62M over the last 12 months. That adds up to net selling of $168.30M. Rhodes Jason P was the most active insider with 79 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Dyne Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DYN's management, answered from reported figures.

Who manages DYN?

Dyne Therapeutics, Inc. (DYN) lists 11 active executives. The top listed executive is Douglas Kerr, Head of Research & Development and Chief Medical Officer.

Are DYN insiders buying or selling?

Recent insider activity shows net selling of $132.49M.